Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
Upcoming Presentation: Neuphoria Therapeutics Inc. will present a pharmacokinetic/pharmacodynamic analysis of its BNC210 drug candidate at the ASCP 2025 Annual Meeting on May 28, 2025, focusing on PTSD treatment.
Company Overview: Neuphoria is a clinical-stage biotechnology company developing therapies for neuropsychiatric disorders, with BNC210 aimed at treating social anxiety disorder and PTSD, and has partnerships for further drug development in Alzheimer's disease.
Trade with 70% Backtested Accuracy
Analyst Views on NEUP
About NEUP
About the author
Neuphoria Urges Shareholders to Support Director Nominees for Maximum Value
- Shareholder Voting Recommendation: Neuphoria Therapeutics Inc. urges shareholders to support its director nominees, particularly Peter Miles Davies and David Wilson, to ensure maximum shareholder value during the strategic review process.
- ISS Recommendation: Institutional Shareholder Services (ISS) issued a report recommending shareholders vote for Neuphoria's nominees, noting that the board acted appropriately in response to the clinical trial failure and capital raise efforts.
- Successful Capital Raise: The board proactively raised capital ahead of the Phase 3 trial data readout, strengthening the company's balance sheet and providing a solid financial foundation for the upcoming strategic review.
- Commitment to Transparency: Neuphoria's board has committed to maintaining transparency throughout the strategic review process and has provided recent updates to shareholders, aiming to bolster confidence in the company's future direction.
Nasdaq Rises 1%; Procter & Gamble Reports Positive Earnings
U.S. Stock Market Performance: U.S. stocks opened higher, with the Nasdaq Composite gaining 1% and the Dow and S&P 500 also showing positive movements. Information technology shares rose by 1.3%, while materials stocks fell by 0.3%.
Procter & Gamble Earnings Report: Procter & Gamble reported better-than-expected earnings and sales for Q3, raising its fiscal 2026 guidance for adjusted EPS and sales, surpassing analyst estimates.
Notable Stock Movements: Wellgistics Health saw a significant increase of 183% after a partnership announcement, while Genenta Science surged 145% due to a collaboration expansion. Conversely, Picard Medical's shares dropped 72%.
Global Market Overview: European shares were mixed, with slight gains in some indices, while Asian markets mostly closed higher. Economic indicators showed an increase in the S&P Global services and manufacturing PMIs for October.
Tuesday's Major Stock Market Highlights: Morning News Summary!
Stock Market News Overview: Tuesday features a wealth of stock market news that traders should monitor closely.
TipRanks Compilation: TipRanks has curated a list of the most significant stock market stories for today.
Importance for Traders: Staying updated on these stories is crucial for traders looking to make informed decisions.
Access to Full Stories: Readers can find all the top stock market stories by visiting TipRanks.
What Caused Neuphoria Therapeutics Stock (NEUP) to Drop 65% Today?
Clinical Trial Update: Neuphoria Therapeutics' stock dropped significantly after the AFFIRM-1 Phase 3 trial of BNC210 for social anxiety disorder failed to meet its primary and secondary endpoints.
Future Plans: The company will cease development of BNC210 for social anxiety disorder and will reassess its potential for treating PTSD, alongside conducting a strategic review of its operations.
Stock Performance: Following the news, Neuphoria's stock fell 67.53% in pre-market trading, despite a year-to-date increase of 348.98%.
Analyst Ratings: The consensus rating for Neuphoria Therapeutics remains a Moderate Buy, with an average price target of $19.43, although these ratings may change due to the recent developments.
Neuphoria Therapeutics Shares Progress on AFFIRM-1 Phase 3 Trial Assessing BNC210 for Treating Acute Social Anxiety Disorder
Trial Results: Neuphoria Therapeutics' AFFIRM-1 Phase 3 trial for BNC210 in treating social anxiety disorder did not meet its primary or secondary endpoints, although the drug's safety profile remained favorable.
Strategic Review: Following the trial results, Neuphoria plans to discontinue its social anxiety disorder program and will conduct a strategic review of its operations and portfolio to maximize shareholder value.
Neuphoria Therapeutics Inc. Sees Decrease in Annual Loss
Financial Performance: Neuphoria Therapeutics Inc. reported a loss of -$0.37 million for the full year, significantly improved from a loss of -$15.49 million the previous year.
Earnings Per Share: The company's earnings per share (EPS) were -$0.23, compared to -$18.62 per share last year, indicating a notable reduction in losses.
Neuphoria Urges Shareholders to Support Director Nominees for Maximum Value
- Shareholder Voting Recommendation: Neuphoria Therapeutics Inc. urges shareholders to support its director nominees, particularly Peter Miles Davies and David Wilson, to ensure maximum shareholder value during the strategic review process.
- ISS Recommendation: Institutional Shareholder Services (ISS) issued a report recommending shareholders vote for Neuphoria's nominees, noting that the board acted appropriately in response to the clinical trial failure and capital raise efforts.
- Successful Capital Raise: The board proactively raised capital ahead of the Phase 3 trial data readout, strengthening the company's balance sheet and providing a solid financial foundation for the upcoming strategic review.
- Commitment to Transparency: Neuphoria's board has committed to maintaining transparency throughout the strategic review process and has provided recent updates to shareholders, aiming to bolster confidence in the company's future direction.
Nasdaq Rises 1%; Procter & Gamble Reports Positive Earnings
U.S. Stock Market Performance: U.S. stocks opened higher, with the Nasdaq Composite gaining 1% and the Dow and S&P 500 also showing positive movements. Information technology shares rose by 1.3%, while materials stocks fell by 0.3%.
Procter & Gamble Earnings Report: Procter & Gamble reported better-than-expected earnings and sales for Q3, raising its fiscal 2026 guidance for adjusted EPS and sales, surpassing analyst estimates.
Notable Stock Movements: Wellgistics Health saw a significant increase of 183% after a partnership announcement, while Genenta Science surged 145% due to a collaboration expansion. Conversely, Picard Medical's shares dropped 72%.
Global Market Overview: European shares were mixed, with slight gains in some indices, while Asian markets mostly closed higher. Economic indicators showed an increase in the S&P Global services and manufacturing PMIs for October.
Tuesday's Major Stock Market Highlights: Morning News Summary!
Stock Market News Overview: Tuesday features a wealth of stock market news that traders should monitor closely.
TipRanks Compilation: TipRanks has curated a list of the most significant stock market stories for today.
Importance for Traders: Staying updated on these stories is crucial for traders looking to make informed decisions.
Access to Full Stories: Readers can find all the top stock market stories by visiting TipRanks.
What Caused Neuphoria Therapeutics Stock (NEUP) to Drop 65% Today?
Clinical Trial Update: Neuphoria Therapeutics' stock dropped significantly after the AFFIRM-1 Phase 3 trial of BNC210 for social anxiety disorder failed to meet its primary and secondary endpoints.
Future Plans: The company will cease development of BNC210 for social anxiety disorder and will reassess its potential for treating PTSD, alongside conducting a strategic review of its operations.
Stock Performance: Following the news, Neuphoria's stock fell 67.53% in pre-market trading, despite a year-to-date increase of 348.98%.
Analyst Ratings: The consensus rating for Neuphoria Therapeutics remains a Moderate Buy, with an average price target of $19.43, although these ratings may change due to the recent developments.
Neuphoria Therapeutics Shares Progress on AFFIRM-1 Phase 3 Trial Assessing BNC210 for Treating Acute Social Anxiety Disorder
Trial Results: Neuphoria Therapeutics' AFFIRM-1 Phase 3 trial for BNC210 in treating social anxiety disorder did not meet its primary or secondary endpoints, although the drug's safety profile remained favorable.
Strategic Review: Following the trial results, Neuphoria plans to discontinue its social anxiety disorder program and will conduct a strategic review of its operations and portfolio to maximize shareholder value.
Neuphoria Therapeutics Inc. Sees Decrease in Annual Loss
Financial Performance: Neuphoria Therapeutics Inc. reported a loss of -$0.37 million for the full year, significantly improved from a loss of -$15.49 million the previous year.
Earnings Per Share: The company's earnings per share (EPS) were -$0.23, compared to -$18.62 per share last year, indicating a notable reduction in losses.
